Skip to main content
Category

Uncategorized

PermanBio 002

Jay Perman, MD

By Uncategorized

 Chancellor – University System of MarylandPermanBio 002

Jay A. Perman, MD, became the fifth chancellor of the University System of Maryland (USM) in January 2020. Prior to this appointment, Dr. Perman, a pediatric gastroenterologist, served as president of the University of Maryland, Baltimore (UMB) for nearly a decade. As UMB president, Dr. Perman strengthened that institution’s ties to the city of Baltimore, growing innovation-based economic development activities and spearheading programs to improve the health and well-being of UMB’s closest neighbors.

Dr. Perman’s UMB presidency was marked by excellence in education and research. Each of UMB’s professional schools—medicine, law, dentistry, pharmacy, nursing, and social work—has been singled out for recognition in national and international publications, most notably in U.S. News & World Report’s Best Graduate Schools, U.S. News & World Report’s Global University Rankings, and the Times Higher Education World University Rankings.

As chancellor, Dr. Perman has committed to advancing higher education affordability for all students in Maryland. He also plans to build on USM’s reputation for educational innovation, particularly in research, economic development, and community engagement.

Dr. Perman received his Doctor of Medicine degree with Distinction in 1972 from Northwestern University. After his residency in pediatrics at Northwestern University Children’s Memorial Hospital, he completed a fellowship in pediatric gastroenterology at Harvard Medical School and at Children’s Hospital Medical Center in Boston in 1977.

 
Michael Friedlander Bio pdf

Dr. Micheal Friedlander

By Uncategorized

Vice President for Health Sciences & Technology, Virginia Tech

Michael Friedlander Bio pdf

Michael Friedlander is the vice president for health sciences and technology at Virginia Tech, where he also serves as the founding executive director of the Fralin Biomedical Research Institute at VTC and the senior dean for research at the Virginia Tech Carilion School of Medicine. He has built the institute’s research programs to over $140 million in current grant value with more than 35 research teams and over 400 investigators and students since its founding in 2010. He has served as the principal investigator on multiple research grants on brain processes that mediate vision, developmental plasticity, and traumatic brain injury. His research has been published in leading journals such as Academic Medicine, Cell, J. Neuroscience, Nature, Neuron, PNAS and Science.

 
KlenkBio 002

Juergen Klenk, Ph. D.

By Uncategorized

Principal – Deloitte Consulting, LLP
KlenkBio 002

Juergen Klenk, Ph.D. is a Principal in Deloitte’s Federal Health Sector. He has a deep technical expertise combined with strong business acumen and a track record of over 20 years of experience in leadership, strategic planning, business development, consulting, project management, science and technology, analytics, and research. Dr. Klenk is highly experienced entrepreneur and thought leader who has demonstrated the ability to start up, grow, and successfully establish innovative businesses in Health Analytics. He has successfully led teams across a wide variety of health and science focused organizations including government health care organizations (e.g., HHS, NIH, FDA, CDC, CMS, and VA), academic medical centers, commercial health care providers, pharmaceutical and biotech companies, and nonprofit organizations. He served as CEO and CTO of a bioinformatics startup company that pioneered AI technology for image and text analytics of biomedical data. For the past 15 years, his work has beeb focused on topics including precision medicine, health data strategy at the intersection of ML/AI, Cloud, and Cyber, clinical trials optimization, health outcomes research, and scientific research and innovation.

Dr. Klenk has authored numerous publications in peer-reviewed journals, holds multiple patents, and has been invited to present at multiple international conferences. He holds a Ph.D. in Mathematics from Eberhard-Karls-Universität Tübingen (Germany), and a masters degree in mathematics and Physics from Eberhard-Karls-Universität Tübingen (Germany), as well as a Project Management Professional (PMP) certification.

 
Briskman

Pete Briskman (Chair)

By Uncategorized

Briskman

Executive Director and Broker Lead for JLL’s Maryland Region

Peter Briskman is the Executive Director and Broker Lead for JLL’s Maryland Region. His primary focus is on Tenant Advisory Services working with Life Science Occupants locally and nationally on complex real estate and leasing strategies for Headquarter transactions, relocations, build-to-suits, renewals, expansions, and consolidations. His applied expertise includes strategic real estate planning, municipal incentive negotiations, lease structuring/transactions, portfolio management, and capital markets investment sales.

He is the recipient of GWCAR’s Commercial Leasing Broker of the Year and has been recognized with GWCAR Office Leasing Transactions of the Year for multiple clients.

 
perceptive nav

Perceptive Navigation

By Uncategorized

perceptive nav

http://perceptivenavigation.com/

Perceptive Navigation, LLC is a Maryland-based medical device company developing solutions for the rapidly growing image-guidance market. The company’s core technology provides for a forward-viewing, image-guided interventional system that seeks to significantly improve both the safety and efficacy of millions of procedures per year in the areas of cardiology, interventional radiology, interventional oncology, and emergency medicine. Perceptive’s first product, the Vu-PathTM Ultrasound Guidance System, will initially be approved for central vascular access, a $1B market in the U.S. alone.

navan web logo landscape 200x470 dk background

Navan Technologies

By Uncategorized

navan web logo landscape 200x470 dk background

https://navan-tech.com/

NAVAN Technologies, Inc. is an enabling technology company commercializing a novel non-viral delivery platform to radically accelerate genetic engineering of human primary cells. The Nanostraw technology, exclusively licensed from Stanford University, provides direct intracellular access into hard-to-transfect primary human cells for efficient delivery of any cargo. By using a physical, non-perturbative mechanism for delivery, the challenges of viral-based cell manufacturing (time, cost and technical difficulties) are eliminated, resulting in fewer, faster operational steps.

LifeGene BioMarks

By Uncategorized

http://lifegenedna.com/

We are the first to show that high risk HPV TrDNA can be quantified with qPCR and Sequence-Capture assays and that high-risk HPV genomes can be assembled from TrDNA. We have developed qPCR and Sequence-Capture, Next-Generation Sequencing-based, HPV-Trans Renal DNA (TrDNA) assays to quantify high risk HPV DNA, which can be useful for cervical cancer screening. Our HPV TrDNA assay compares favorably in Specificity and Sensitivity to commercial HPV tests, making them an ideal alternative for low resource settings.

Search

You have successfully subscribed to the newsletter

There was an error while trying to send your request. Please try again.

BioHealth Innovation will use the information you provide on this form to be in touch with you and to provide updates and marketing.